A Randomized, Double-Blind, Placebo-Controlled, Phase I Clinical Study Evaluating the Safety of a Single Ascending Dose of STI-1558 in Healthy Subjects and the Safety, Pharmacokinetics, and Efficacy of Multiple Ascending Doses of STI-1558 in SARS-CoV-2-Positive Subjects
Latest Information Update: 16 Aug 2023
At a glance
- Drugs Olgotrelvir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Zhejiang ACEA Pharmaceutical
Most Recent Events
- 10 Aug 2023 Status changed from active, no longer recruiting to completed.
- 09 Jan 2023 Results (n=78) published in a Sorrento Therapeutics media release.
- 01 Dec 2022 New trial record